Investor Relations Home

Profile
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries.
Stock Quote
IRIX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$7.11
Change (%) Stock is Up 0.10 (1.43%)
Volume7,385
Data as of 05/22/18 3:58 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
05/03/18IRIDEX Announces 2018 First Quarter Financial Results
MOUNTAIN VIEW, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today reported financial results for the first quarter ended March 31, 2018. First Quarter Highlights Cyclo G6™ product revenue increased approximately 50% year-over-year Shipped a record 11,600 G6 probes Shipped 99 G6 laser systems Presence at American Society of Cataract and Refractive Surgery (ASCRS) and Association for Research in Vision and Ophthalmology (ARVO) meetings i... 
Printer Friendly Version
04/19/18IRIDEX to Report First Quarter 2018 Financial Results on May 3, 2018
MOUNTAIN VIEW, Calif., April 19, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced the Company will release financial results for the first quarter 2018 after the close of trading on Thursday, May 3, 2018.  The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international ... 
Printer Friendly Version
04/16/18IRIDEX Announces Appointment of Maria Sainz and David Bruce to its Board of Directors
MOUNTAIN VIEW, Calif., April 16, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) today announced the appointment of Maria Sainz and David Bruce to the Company’s Board of Directors effective as of April 13, 2018.  Ms. Sainz and Mr. Bruce will both join the Compensation Committee. Ms. Sainz will also join the Nominating and Governance Committee.  Concurrent with these additions, George Marcellino will depart from the Board of Directors to focus on his new role as IRIDEX’s Vice Presiden... 
Printer Friendly Version
03/20/18Iridex Receives CE Mark for Transilluminated Probe
The leading-edge G-Probe Illuminate™ glaucoma device with built-in transillumination now available in Europe MOUNTAIN VIEW, Calif., March 20, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX) is pleased to announce the availability of the G-Probe Illuminate™ device in Europe. The probe, now with CE mark, offers combined transillumination and laser fiber for targeted transscleral cyclophotocoagulation (CPC). The G-Probe Illuminate received FDA clearance and was launched in early 2017. ... 
Printer Friendly Version
Primary IR Contact
Lynn Lewis or Leigh Salvo
Phone: (415) 937-5404
E-mail: investors@iridex.com


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.


logo aa0logo agslogo ascrslogo asrslogo esrs0logo euretina